Depression, Fatigue Not Linked to Cancer

"Vital exhaustion" - the energy-draining combination of depression and fatigue - does not increase the risk of cancer, according to a large prospective study from Denmark. Although people who reported the most vital exhaustion exercised less and smoked more than their more energetic peers, they were still not at increased risk for any cancer, according to a study reported in the August 8 online edition of Cancer.



"We deduce that there is neither a direct positive influence of vital exhaustion on cancer risk via an immune mechanism nor an indirect association promoted by unhealthy life style factors," wrote the authors from the Danish Cancer Society in Copenhagen.



The researchers investigated the possibility of a cancer link after discovering that vital exhaustion increased risk for heart attacks and all-cause mortality. With questionnaire results from 8,500 people already in hand through the long-running Copenhagen City Heart Study, the authors linked the results to the Danish Cancer Registry, which records every diagnosis in the country of 5.4 million people. The questionnaires completed from 1991 to 1994 and the cancer data collected in 2002 resulted in a mean follow-up time of 8.6 years.



The authors cautioned that selection bias could have been at play - that is, the most eager study participants tended to be the healthiest. Only 61 percent of the original heart study participants completed the exhaustion questionnaire.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap